Next Article in Journal
E-Cigarettes or Heat-not-Burn Tobacco Products: Advantages or Disadvantages for the Lungs of Smokers
Previous Article in Journal
CT Imaging Features of Thin-Walled Cavitary Squamous Cell Lung Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
ARM
Volume 87
Issue 2
10.5603/ARM.2019.0019
arm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Advances in Respiratory Medicine is published by MDPI from Volume 90 Issue 4 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Via Medica.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Cell-Free Tumour DNA as a Diagnostic and Prognostic Biomarker in Non-small Cell Lung Carcinoma

by
Barbara Łochowska
1,*,
Dariusz Nowak
2 and
Piotr Białasiewicz
1
1
Department of Sleep Medicine and Metabolic Disorders, Medical University of Lodz, Poland
2
Department of Clinical Physiology, Medical University of Lodz, Poland
*
Author to whom correspondence should be addressed.
Adv. Respir. Med. 2019, 87(2), 118-122; https://doi.org/10.5603/ARM.2019.0019
Submission received: 15 January 2019 / Revised: 14 April 2019 / Accepted: 14 April 2019 / Published: 18 April 2019

Abstract

More than 1 million people dies worldwide due to lung cancer which is the first most incident cancer in males and the third in females. Only early diagnosis makes possible to achieve long-lasting remission or even cure the disease. Unfortunately, no tumour marker to achieve this goal has been identified, yet. One of putative lung cancer markers is free circulating tumor DNA. Its concentration seems to be related to cancer burden. Moreover, it can be subjected to mutational status analysis allowing for introduction of targeted treatment. This led to the idea of liquid biopsy which can substitute for a standard biopsy not feasible in certain clinical circumstances. Assessment of cell free tumour DNA can also inform about progression/recurrence of cancer and may have a prognostic value. Therefore, the aim of this article is to review on free circulating DNA as a potential marker in lung cancer.
Keywords: free circulating DNA; liquid biopsy; lung cancer; biomarker free circulating DNA; liquid biopsy; lung cancer; biomarker

Share and Cite

MDPI and ACS Style

Łochowska, B.; Nowak, D.; Białasiewicz, P. Cell-Free Tumour DNA as a Diagnostic and Prognostic Biomarker in Non-small Cell Lung Carcinoma. Adv. Respir. Med. 2019, 87, 118-122. https://doi.org/10.5603/ARM.2019.0019

AMA Style

Łochowska B, Nowak D, Białasiewicz P. Cell-Free Tumour DNA as a Diagnostic and Prognostic Biomarker in Non-small Cell Lung Carcinoma. Advances in Respiratory Medicine. 2019; 87(2):118-122. https://doi.org/10.5603/ARM.2019.0019

Chicago/Turabian Style

Łochowska, Barbara, Dariusz Nowak, and Piotr Białasiewicz. 2019. "Cell-Free Tumour DNA as a Diagnostic and Prognostic Biomarker in Non-small Cell Lung Carcinoma" Advances in Respiratory Medicine 87, no. 2: 118-122. https://doi.org/10.5603/ARM.2019.0019

APA Style

Łochowska, B., Nowak, D., & Białasiewicz, P. (2019). Cell-Free Tumour DNA as a Diagnostic and Prognostic Biomarker in Non-small Cell Lung Carcinoma. Advances in Respiratory Medicine, 87(2), 118-122. https://doi.org/10.5603/ARM.2019.0019

Article Metrics

Back to TopTop